Concert Pharmaceuticals Inc
NASDAQ:CNCE
Concert Pharmaceuticals Inc
Revenue
Concert Pharmaceuticals Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Concert Pharmaceuticals Inc
NASDAQ:CNCE
|
Revenue
$32.6m
|
CAGR 3-Years
46%
|
CAGR 5-Years
177%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
9%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
Concert Pharmaceuticals Inc
Revenue Breakdown
Breakdown by Geography
Concert Pharmaceuticals Inc
Breakdown by Segments
Concert Pharmaceuticals Inc
Total Revenue:
32.6m
USD
|
Other Revenue:
32.5m
USD
|
License And Research And Development Revenue:
39k
USD
|
See Also
What is Concert Pharmaceuticals Inc's Revenue?
Revenue
32.6m
USD
Based on the financial report for Dec 31, 2021, Concert Pharmaceuticals Inc's Revenue amounts to 32.6m USD.
What is Concert Pharmaceuticals Inc's Revenue growth rate?
Revenue CAGR 5Y
177%
Over the last year, the Revenue growth was 312%. The average annual Revenue growth rates for Concert Pharmaceuticals Inc have been 46% over the past three years , 177% over the past five years .